Navigation Links
MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System
Date:6/17/2008

WARRENDALE, Pa., June 17 /PRNewswire/ -- MEDRAD, INC., announced today that it received FDA 510(k) clearance for a new Fluorodeoxyglucose (FDG) Infusion System for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures. The new Intego(TM) PET Infusion System is the first infusion system available in the United States to automate the FDG delivery process.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

In automating and controlling the FDG delivery process, the Intego System enables the healthcare provider to easily administer FDG at any time throughout the day and enhances the clinician's ability to deliver FDG with precision, flexibility, and safety.

The Intego System automatically extracts a patient dose from a multi-dose vial and delivers it directly to the patient, virtually eliminating manual dose preparation and handling, and the corresponding radiation exposure to the technologist. With the Intego System's dose-on-demand capability, the prescribed dose can be delivered when the patient and technologist are ready, enabling technologists to easily and efficiently respond to schedule changes, patient delays, and add-on patients. Innovative features, including real-time dose availability information, an integrated ionization chamber, and an optional weight-based dose calculation, allow the healthcare provider to more precisely customize each patient's dose. Safety features include a tungsten multi-dose vial shield, a fully lead-lined mobile cart, and an automated saline flush to remove residual FDG from the line after each infusion.

"MEDRAD has a strong heritage of developing innovative products to improve fluid delivery for Cardiovascular (CV), Magnetic Resonance (MR) and Computed Tomography (CT) imaging procedures. With our new Intego system that fully automates FDG delivery, we can once again improve how molecular imaging is done," said Cliff Kress, senior vice president, CT Business Unit.

MEDRAD is working with FDG suppliers to provide FDG in multi-dose vials and vial shields compatible with the Intego System and recently announced a distribution and co-marketing agreement with the largest PET radiopharmacy network, PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions USA, Inc.

About MEDRAD

MEDRAD, INC., is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.

Cautionary statement regarding forward-looking statement.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC., undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE MEDRAD, INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award
2. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
3. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
4. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
5. Xenon Receives BIOTECanada Gold Leaf Award
6. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
7. Advance Nanotechs Owlstone Subsidiary Receives Order From IEE
8. Met-Pro Corporations Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000
9. CryoLifes BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
10. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
11. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Meister Media Worldwide ... fresh look and added functionality give the agricultural world a taste of Meister ... shift in agriculture – from precision farming via satellites and Unmanned Aerial Vehicles ...
(Date:4/29/2016)... ... 2016 , ... The MIT bioLogic design team has won multiple A' ... properties can be applied to fabric and formed into living interfaces between body and ... humidity change. The team harvested Natto cells and applied them to fabric with custom ...
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that the two-level ... sale in the United States. These components expand the capabilities of the system ... sales beginning in October of 2015, the company has seen significant sales growth in ...
Breaking Biology Technology:
(Date:3/17/2016)... LONDON , March 17, 2016 ... market intelligence, forecasts the global biometrics market will ... an impressive 118% increase from 2015. Consumer electronics, ... with embedded fingerprint sensors anticipated to reach two ... Dimitrios Pavlakis , Research Analyst ...
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):